Blunted response of growth hormone to clonidine and apomorphine in endogenous depression. 1988

M Ansseau, and R Von Frenckell, and J L Cerfontaine, and P Papart, and G Franck, and M Timsit-Berthier, and V Geenen, and J J Legros
Biological Psychiatry and Psychopharmacology Unit, Centre Hospitalier Universitaire, Liège Sart Tilman, Belgium.

We measured the growth hormone (GH) response to clonidine (an alpha-2-adrenergic agonist) and to apomorphine (a dopaminergic agonist) in 15 major endogenous and 15 minor depressive in-patients matched for gender and age. Results showed a significantly smaller GH response in the major depressives to both clonidine (P less than 0.01) and apomorphine (P less than 0.001). No significant difference existed between the two groups with regard to changes in blood pressure and pulse rate during either test. While major depressives showed a trend toward smaller sedative side-effects than minor depressives after clonidine, they showed significantly smaller sedative and gastro-intestinal side-effects after apomorphine. No significant correlation was present either in the major depressive or in the minor depressive group between the GH responses following clonidine and apomorphine challenges. These results support the hypothesis of both noradrenergic and dopaminergic neurotransmitter disturbances in major depression, with individual variability with regard to those biochemical anomalies.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011674 Pulse The rhythmical expansion and contraction of an ARTERY produced by waves of pressure caused by the ejection of BLOOD from the left ventricle of the HEART as it contracts. Pulses
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003000 Clonidine An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION. Catapres,Catapresan,Catapressan,Chlophazolin,Clofelin,Clofenil,Clonidine Dihydrochloride,Clonidine Hydrochloride,Clonidine Monohydrobromide,Clonidine Monohydrochloride,Clopheline,Dixarit,Gemiton,Hemiton,Isoglaucon,Klofelin,Klofenil,M-5041T,ST-155,Dihydrochloride, Clonidine,Hydrochloride, Clonidine,M 5041T,M5041T,Monohydrobromide, Clonidine,Monohydrochloride, Clonidine,ST 155,ST155
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001058 Apomorphine A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. Apokinon,Apomorphin-Teclapharm,Apomorphine Chloride,Apomorphine Hydrochloride,Apomorphine Hydrochloride Anhydrous,Apomorphine Hydrochloride, Anhydrous,Apomorphine Hydrochloride, Hemihydrate,Britaject,Apomorphin Teclapharm

Related Publications

M Ansseau, and R Von Frenckell, and J L Cerfontaine, and P Papart, and G Franck, and M Timsit-Berthier, and V Geenen, and J J Legros
September 1986, Biological psychiatry,
M Ansseau, and R Von Frenckell, and J L Cerfontaine, and P Papart, and G Franck, and M Timsit-Berthier, and V Geenen, and J J Legros
January 1988, The British journal of psychiatry : the journal of mental science,
M Ansseau, and R Von Frenckell, and J L Cerfontaine, and P Papart, and G Franck, and M Timsit-Berthier, and V Geenen, and J J Legros
May 1987, The American journal of psychiatry,
M Ansseau, and R Von Frenckell, and J L Cerfontaine, and P Papart, and G Franck, and M Timsit-Berthier, and V Geenen, and J J Legros
June 1984, The British journal of psychiatry : the journal of mental science,
M Ansseau, and R Von Frenckell, and J L Cerfontaine, and P Papart, and G Franck, and M Timsit-Berthier, and V Geenen, and J J Legros
February 2004, Psychoneuroendocrinology,
M Ansseau, and R Von Frenckell, and J L Cerfontaine, and P Papart, and G Franck, and M Timsit-Berthier, and V Geenen, and J J Legros
June 2010, Journal of psychopharmacology (Oxford, England),
M Ansseau, and R Von Frenckell, and J L Cerfontaine, and P Papart, and G Franck, and M Timsit-Berthier, and V Geenen, and J J Legros
September 1995, Biological psychiatry,
M Ansseau, and R Von Frenckell, and J L Cerfontaine, and P Papart, and G Franck, and M Timsit-Berthier, and V Geenen, and J J Legros
February 1991, Archives of general psychiatry,
M Ansseau, and R Von Frenckell, and J L Cerfontaine, and P Papart, and G Franck, and M Timsit-Berthier, and V Geenen, and J J Legros
January 1994, Psychoneuroendocrinology,
M Ansseau, and R Von Frenckell, and J L Cerfontaine, and P Papart, and G Franck, and M Timsit-Berthier, and V Geenen, and J J Legros
January 1981, The British journal of psychiatry : the journal of mental science,
Copied contents to your clipboard!